Washburn Capital Management Inc. Purchases New Position in Johnson & Johnson $JNJ

Washburn Capital Management Inc. acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) in the third quarter, HoldingsChannel.com reports. The institutional investor acquired 4,157 shares of the company’s stock, valued at approximately $1,101,000. Johnson & Johnson accounts for approximately 0.5% of Washburn Capital Management Inc.’s holdings, making the stock its 27th biggest holding.

Several other institutional investors and hedge funds have also added to or reduced their stakes in JNJ. Prairie Advisory LLC boosted its position in Johnson & Johnson by 100.2% in the third quarter. Prairie Advisory LLC now owns 3,382 shares of the company’s stock valued at $896,000 after buying an additional 1,693 shares in the last quarter. Herold Advisors Inc. grew its stake in shares of Johnson & Johnson by 2.4% during the third quarter. Herold Advisors Inc. now owns 15,627 shares of the company’s stock worth $4,137,000 after buying an additional 360 shares during the last quarter. LexAurum Advisors LLC grew its stake in shares of Johnson & Johnson by 0.6% during the third quarter. LexAurum Advisors LLC now owns 54,885 shares of the company’s stock worth $14,530,000 after buying an additional 328 shares during the last quarter. Jackson Square Capital LLC increased its holdings in shares of Johnson & Johnson by 7.6% during the third quarter. Jackson Square Capital LLC now owns 8,354 shares of the company’s stock worth $2,212,000 after buying an additional 587 shares in the last quarter. Finally, Kaufman Rossin Wealth LLC acquired a new position in shares of Johnson & Johnson during the third quarter worth $214,000. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of a number of research reports. The Goldman Sachs Group reiterated a “buy” rating and issued a $282.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Weiss Ratings upgraded Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 8th. Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a research report on Monday, August 3rd. Wells Fargo & Company upped their target price on Johnson & Johnson from $275.00 to $287.00 and gave the stock an “overweight” rating in a report on Friday. Finally, JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a research report on Tuesday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $275.92.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: MedTech launch supports growth: J&J introduced the next-generation Shockwave C2 Aero Fly coronary intravascular lithotripsy catheter in the U.S. The device delivers pulses at 2 Hz and is designed to reduce treatment time for calcified coronary lesions, potentially improving physician adoption and strengthening J&J’s cardiovascular portfolio. J&J launches Shockwave C2 Aero Fly catheter
• Positive Sentiment: Pipeline data remains constructive: TREMFYA maintained or improved remission in Crohn’s disease patients with perianal fistulas through 48 weeks, supporting the drug’s potential expansion and helping offset concerns about future competition to older products. J&J TREMFYA Crohn’s disease data
• Positive Sentiment: Supportive analyst view: TD Cowen reiterated a Buy rating and $300 price target, citing underappreciated pharmaceutical and MedTech growth. J&J’s latest quarterly results also exceeded EPS and revenue expectations, providing a favorable earnings backdrop.
• Neutral Sentiment: Acquisition strategy under review: Analysts see growing sales from acquired heart technologies and a larger hospital network, but competition, development costs and the need to convert revenue growth into stronger ownership returns remain concerns. J&J medical device deals analysis
• Negative Sentiment: Competitive and valuation risks: Rapport reported positive Phase II results for a novel oral bipolar drug licensed from J&J, potentially creating a future competitor to J&J’s Caplyta. Separately, JLPascual downgraded J&J to Sell, while commentary highlights that the stock trades at a premium multiple and must sustain earnings growth to justify it.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $259.42 on Wednesday. The firm has a market cap of $625.17 billion, a PE ratio of 39.31, a price-to-earnings-growth ratio of 2.51 and a beta of 0.21. The firm’s fifty day moving average is $265.53 and its 200-day moving average is $249.84. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. Johnson & Johnson has a 52 week low of $184.66 and a 52 week high of $281.07.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. Johnson & Johnson’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Sell-side analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s payout ratio is presently 81.21%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,367,458. This represents a 48.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 64,515 shares of company stock worth $17,271,766. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.